Active Ingredient History
Amiloride, an antikaliuretic-diuretic agent, is a pyrazine-carbonyl-guanidine that is unrelated chemically to other known antikaliuretic or diuretic agents. It is an antihypertensive, potassium-sparing diuretic that was first approved for use in 1967 and helps to treat hypertension and congestive heart failure. The drug is often used in conjunction with thiazide or loop diuretics. Due to its potassium-sparing capacities, hyperkalemia (high blood potassium levels) are occasionally observed in patients taking amiloride. Amiloride works by inhibiting sodium reabsorption in the distal convoluted tubules and collecting ducts in the kidneys by binding to the amiloride-sensitive sodium channels. This promotes the loss of sodium and water from the body, but without depleting potassium. It is used for as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Albuminuria (Phase 4)
Attention Deficit Disorder with Hyperactivity (Early Phase 1)
Bipolar Disorder (Phase 4)
Cardiovascular Diseases (Phase 3)
Coronary Artery Disease (Phase 2/Phase 3)
Coronary Disease (Phase 2/Phase 3)
Cystic Fibrosis (Phase 2)
Diabetes Mellitus, Type 2 (Phase 4)
Edema (Phase 3)
Essential Hypertension (Phase 4)
Gastroesophageal Reflux (Phase 1)
Heartburn (Phase 1)
Heart Failure (Phase 3)
Hyperparathyroidism, Primary (Phase 2/Phase 3)
Hypertension ()
Hypoparathyroidism (Phase 2)
Insulin Resistance (Phase 2/Phase 3)
Migraine with Aura (Phase 2)
Multiple Sclerosis (Phase 2)
Multiple Sclerosis, Chronic Progressive (Phase 2)
Nephrotic Syndrome (Phase 3)
Obesity (Phase 2/Phase 3)
Optic Neuritis (Phase 2)
Pharmacokinetics (Early Phase 1)
Polycystic Kidney, Autosomal Dominant (Phase 4)
Prehypertension (Phase 4)
Proteinuria (Phase 4)
Renal Insufficiency, Chronic (Phase 4)
Sleep Apnea Syndromes (Phase 3)
Sodium (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
